Why Crinetics Pharmaceuticals Stock Was Sliding on Friday
Key Points
The biotech unveiled its third-quarter results.
They didn't meet analyst expectations, but there was good news in the update.
- 10 stocks we like better than Crinetics Pharmaceuticals ›
The stock of biotech Crinetics Pharmaceuticals (NASDAQ: CRNX) wasn't ending the trading week on a high note. In late-session action on Friday, the company's share price was down by more than 8% on a quarterly earnings report that clearly wasn't impressing the market. By comparison, the benchmark S&P 500 index was underwater by only 1.1% at that point.
Gearing up for commercialization
For its third quarter, Crinetics earned $143,000 in revenue, derived fully from a licensing agreement with Japanese pharmaceutical company Sanwa Kagaku Kenkyusho. The deal with the company's Asian peer covers Crinetics' acromegaly treatment paltusotine (brand name: Palsonify), which was approved by the U.S. Food and Drug Administration (FDA) in late September.
Where to invest $1,000 right now? Our analyst team just revealed what they believe are the 10 best stocks to buy right now. Continue »
Image source: Getty Images.
On the bottom line, Crinetics' net loss according to generally accepted accounting principles (GAAP) deepened to over $130 million, or $1.38 per share, from the year-ago deficit of under $77 million.
Those figures didn't meet the average analyst estimates, which were $491,000 for revenue and $1.25 per share for GAAP net loss.
In the earnings release, Crinetics quoted founder and CEO Scott Struthers as saying that the commercial rollout of Palsonify was "off to a very good start."
A time of transformation
"With the approval milestone, we are now a fully integrated pharmaceutical company. Five clinical trials across our deep pipeline are advancing and our financial position remains robust," Struthers added.
The financials of biotech stocks, due to their dependence on the often rocky process of drug development, can be volatile. This is why they're often far from the consensus analyst projections. With Palsonify coming to market, Crinetics seems to be better positioned for success than Friday's investor reaction might suggest.
Should you invest $1,000 in Crinetics Pharmaceuticals right now?
Before you buy stock in Crinetics Pharmaceuticals, consider this:
The Motley Fool Stock Advisor analyst team just identified what they believe are the 10 best stocks for investors to buy now… and Crinetics Pharmaceuticals wasn’t one of them. The 10 stocks that made the cut could produce monster returns in the coming years.
Consider when Netflix made this list on December 17, 2004... if you invested $1,000 at the time of our recommendation, you’d have $591,613!* Or when Nvidia made this list on April 15, 2005... if you invested $1,000 at the time of our recommendation, you’d have $1,152,905!*
Now, it’s worth noting Stock Advisor’s total average return is 1,034% — a market-crushing outperformance compared to 191% for the S&P 500. Don’t miss out on the latest top 10 list, available when you join Stock Advisor.
See the 10 stocks »
*Stock Advisor returns as of November 3, 2025
Eric Volkman has no position in any of the stocks mentioned. The Motley Fool has no position in any of the stocks mentioned. The Motley Fool has a disclosure policy.
Recommended Articles
